Palvella Therapeutics (PVLA) Expected to Announce Quarterly Earnings on Thursday

Palvella Therapeutics (NASDAQ:PVLA) is expected to announce its Q1 2025 earnings results before the market opens on Thursday, May 15th. Analysts expect the company to announce earnings of ($3.40) per share for the quarter.

Palvella Therapeutics Stock Up 11.4%

Shares of PVLA opened at $23.12 on Wednesday. The company has a market capitalization of $255.31 million, a PE ratio of -1.91 and a beta of 0.10. The firm’s fifty day moving average price is $24.87. Palvella Therapeutics has a 12 month low of $6.20 and a 12 month high of $29.27.

Wall Street Analyst Weigh In

A number of analysts have commented on PVLA shares. Canaccord Genuity Group reaffirmed a “buy” rating and set a $39.00 price target on shares of Palvella Therapeutics in a research report on Wednesday, February 26th. Scotiabank assumed coverage on shares of Palvella Therapeutics in a report on Friday, March 7th. They issued a “sector outperform” rating and a $50.00 target price on the stock. HC Wainwright reiterated a “buy” rating and issued a $38.00 price objective on shares of Palvella Therapeutics in a research note on Wednesday, April 30th. Jones Trading assumed coverage on shares of Palvella Therapeutics in a research note on Tuesday, March 25th. They issued a “buy” rating and a $45.00 price objective for the company. Finally, TD Cowen began coverage on shares of Palvella Therapeutics in a research note on Wednesday, February 5th. They issued a “buy” rating and a $44.00 price objective for the company. Seven research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $44.43.

Insider Activity

In related news, Director George M. Jenkins bought 2,500 shares of Palvella Therapeutics stock in a transaction dated Wednesday, April 9th. The stock was purchased at an average cost of $20.13 per share, with a total value of $50,325.00. Following the transaction, the director now directly owns 183,171 shares of the company’s stock, valued at approximately $3,687,232.23. The trade was a 1.38% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 6.39% of the company’s stock.

Palvella Therapeutics Company Profile

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.